Clinical trial · Interventional
Engineered Dendritic Cell Vaccines for Multiple Myeloma
Engineered Dendritic Cell Vaccines for Remission Maintenance in Multiple Myeloma Patients
NCT06435910CI-TRIAL-00124258not yet recruitingPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine the feasibility, safety, and efficacy of dendritic cell (DC) vaccines in the treatment of multiple myeloma (MM) or plasmacytoma based on immune-modified DC vaccines (DCvac). This approach is aimed to achieve prolonged maintenance of remission in multiple myeloma or plasmacytoma patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma or Plasmacytoma | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| DC vaccines | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- DCvac cells to treat MM
- interventionNames
- Biological: DC vaccines
Primary outcomes (1)
- measure
- Safety of DC injection
- timeFrame
- 1 Month
- description
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Secondary outcomes (1)
- measure
- Clinical response
- timeFrame
- 1 year
- description
- Anti-tumor activity of the DCvacs by examination of anti-cancer immunity by measurement of tumor burden
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Male and female subjects with multiple myeloma or plasmacytoma * Very good partial or complete remission (CR) after prior combination therapies. * Expected survival \> 12 weeks * Adequate venous access for blood withdrawal or apheresis, and no other contraindications for blood withdrawal * Voluntary informed consent is given with willingness to continue follow up Exclusion Criteria: * Pregnant or lactating women * Uncontrolled active infection * HIV or active hepatitis B or hepatitis C infection * Concurrent use of systemic steroids; the use of inhaled steroids is not exclusionary
References
Publications (2)
- BACKGROUNDHan S, Wang B, Cotter MJ, Yang LJ, Zucali J, Moreb JS, Chang LJ. Overcoming immune tolerance against multiple myeloma with lentiviral calnexin-engineered dendritic cells. Mol Ther. 2008 Feb;16(2):269-79. doi: 10.1038/sj.mt.6300369. Epub 2007 Dec 11. PMID 18071334
- BACKGROUNDAyed AO, Chang LJ, Moreb JS. Immunotherapy for multiple myeloma: Current status and future directions. Crit Rev Oncol Hematol. 2015 Dec;96(3):399-412. doi: 10.1016/j.critrevonc.2015.06.006. Epub 2015 Jun 28. PMID 26153389